KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Operations: 2009-2025

Historic Cash from Operations for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to $74.3 million.

  • Acadia Pharmaceuticals' Cash from Operations rose 17.46% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year decrease of 1.86%. This contributed to the annual value of $157.7 million for FY2024, which is 844.31% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Cash from Operations of $74.3 million as of Q3 2025, which was up 16.15% from $64.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Cash from Operations high stood at $85.4 million for Q4 2023, and its period low was -$76.3 million during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' Cash from Operations had a median value of $29.1 million in 2024 and averaged $30.3 million.
  • Within the past 5 years, the most significant YoY rise in Acadia Pharmaceuticals' Cash from Operations was 457.97% (2023), while the steepest drop was 8,009.35% (2023).
  • Over the past 5 years, Acadia Pharmaceuticals' Cash from Operations (Quarterly) stood at -$23.1 million in 2021, then dropped by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then plummeted by 52.71% to $40.4 million in 2024, then climbed by 17.46% to $74.3 million in 2025.
  • Its last three reported values are $74.3 million in Q3 2025, $64.0 million for Q2 2025, and $20.3 million during Q1 2025.